3 / 4
Volume 7, Issue 5 (Suppl)
J Biotechnol Biomater
ISSN: 2155-952X JBTBM, an open access journal
Biotechnology 2017
November 13-14, 2017
Page 12
conference
series
.com
November 13-14, 2017 Osaka, Japan
19
th
World Congress on
Biotechnology
Glycosylation of therapeutic proteins: Functions and analytical innovation
G
lycosylation is a critical quality attribute of therapeutic glycoproteins, including monoclonal antibodies (mAbs), which
can directly affect product safety and efficacy. However, the complexity of protein glycosylation poses a daunting analytical
challenge. The current methods for glycan analysis (e.g., mass spectrometry) consist of laborious enzymatic digestion protocols
and analyses of the resulting free glycans and aglycosylated proteins. This presentation describes an innovative lectin-
based microarray approach for high throughput glycan analysis of native proteins. Case studies of commercial therapeutic
glycoproteins will be discussed to highlight the applications of the lectin microarray platforms for the characterization of
biotechnology products.
Biography
Baolin Zhang is a Senior Investigator and Review Team Leader in the Office of Biotechnology Products of the Center for Drug Evaluation and Research (CDER)
at the US Food and Drug Administration (FDA). He has 15 years of FDA experience regulating biotechnology drug product applications, including monoclonal
antibodies and biosimilars. He also directs a research program on advancing analytics for biotechnology products. He has published over 80 original studies in high
profile journals and presented at numerous scientific and regulatory conferences. He has received numerous awards for excellence in scientific achievement and
for mentoring junior scientists including FDA Excellence in Laboratory Science and Excellence in Leadership.
Baolin.Zhang@fda.hhs.govBaolin Zhang
Food and Drug Administration, USA
Baolin Zhang, J Biotechnol Biomater 2017, 7:5 (Suppl)
DOI: 10.4172/2155-952X-C1-081